TUMOR INDUCTION BY MURINE SARCOMA VIRUS IN AKR AND C58 MICE : Reduction of Tumor Regression Associated with Appearance of Gross Leukemia Virus Pseudotypes by Chieco-Bianchi, Luigi et al.
TUMOR  INDUCTION  BY  MURINE  SARCOMA  VIRUS  IN 
AKR  AND  C58  MICE 
Reduction of Tumor Regression Associated with Appearance of 
Gross Leukemia Virus Pseudotypes*$ 
B~ LUIGI CHIECO-BIANCHI, ALFONSO COLOMBATTI, DINO COLLAVO,  FUJIRO SENDO, 
TADAO AOKI, AND PETER J.  FISCHINGER 
(From  the Laboratory  of Experimental Oncology,  Institute of Pathological  Anatomy,  University of 
Padova, and the Viral Leukemia and Lymphoma Branch, National Cancer Institute, National 
Institutes of Health, Bethesda, Maryland 20014) 
A  common  feature of avian and mammalian  sarcoma  viruses is the induction of 
soft  tissue  sarcomas  which  are  characterized  in  the  species  of origin  by a  very 
short latent period and by a  high frequency of complete spontaneous regressions. 
This unique  property is not shared by any other oncogenic agents,  either viral or 
chemical  in  nature,  since  the  tumors  they  induce  usually  arise  after  weeks  or 
months  and  show  a  fatal progressive growth. 
Some strains of sarcoma virus are considered defective for replication in the sense that 
they  are  apparently unable  to  synthetize an  outer  envelope,  and  consequently  cannot 
produce an  infectious virus progeny. As shown  first in  the avian  (1),  and subsequently 
confirmed in the murine (2) and in the feline systems (3), type C leukemia viruses can act 
as helpers for sarcoma virus replication by providing envelope components necessary for 
infection. Infectious sarcoma particles then  possess the surface specificities of the helper 
virus as to host range and antigenicity. 
Virus  preparations  commonly  used  to  produce  tumors  in  animals  contain  a  dual 
population of sarcoma and  leukemia viruses mixed in variable ratios. In the mouse,  the 
Moloney murine sarcoma virus (M-MSV) 1 induces tumors which release infectious virus 
whose envelope antigens are specified by the associated helper Moloney murine leukemia 
virus (M-MuLV)  (4). Furthermore, the new surface antigens acquired by neoplastic cells 
appear  to  be  largely similar to  those  determined  by M-MuLV  (5).  The  vigorous  host 
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immune  response  evoked  by  tumor  tissue  is  known  to  be  directed  mostly  against 
M-MuLV-coded antigens. It is believed that the regression of tumors observed in adult 
mice injected with M-MSV is largely dependent on the humoral and cellular immune 
reactions elicited by the strongly antigenic sarcomas. Suckling mice or adults immuno- 
suppressed by various treatments develop progressively growing tumors following injec- 
tion with M-MSV (5). Nonspecific stimulation of the immune system, on the other hand, 
significantly inhibits M-MSV tumorigenesis (6). 
Potentiation of M-MSV tumor induction has also been observed in mice preinfected 
with  MuLVs  (7,  8).  In  previous  experiments (9  and  footnote  2),  we  have  found that 
BALB/c, CBA, and (C58BL/6  x  AKR)F~ mice neonatally infected with Graffi (Gi-) or 
passage A Gross (G-) MuLV showed an increased tumor incidence after inoculation of 
M-MSV.  More  significantly,  the  great  majority  of  tumors  grew  progressively  and 
eventually killed the host. The MSV recovered from these tumors was readily neutralized 
by antisera specific against Gi- or  G-MuLV, but not by an antiserum directed against 
M-MSV.  It  was  concluded  that  the  tumors  were  actually  caused  by  a  new  MSV 
pseudotype possessing the antigenic specificity of the coinfecting Gi- or G-MuLV. Addi- 
tionally, a state of partial tolerance (see Discussion) present in MuLV neonatally infected 
mice could account for the lack of regression of these MSV-induced sarcomas. 
In  the  present  experiments,  we  investigated the  in  vivo  interaction between 
MuLV  and MSV  in a  more  natural setting. Mice of the high leukemia strains 
AKR and C58,  commonly considered as natural carriers of wild type G-MuLV, 
have  been examined for  their oncogenic response to M-MSV.  In addition, the 
biology of tumors,  the  host  immune  reactivity, and the antigenic properties of 
retrieved MSV have been studied. 
Materials and Methods 
Mice.  AKR, C58, BALB/c, and C57BL/6 (hereafter called BALB and B6, respectively) mice were 
obtained from the colony of the Laboratory  of Experimental Oncology, Padova University, and from 
the  Animal Production  Branch,  Division  of Research  Services,  National Institutes of  Health, 
Bethesda, Md. Since a similar tumor response to M-MSV was observed in mice of a given strain from 
the two sources, no distinction has been made in reporting the experimental results. 
Viruses.  The M-MSV has been maintained by serial in vivo passages in 1- to 2-week old BALB 
mice. A cell-free extract from pooled neoplastic tissues was prepared by homogenization and differen- 
tial centrifugation according  to the Moloney procedure  (10). In the experiments performed  at the 
National Cancer Institute, Bethesda,  Md., the M-MSV preparation no. 240, obtained through the 
courtesy of Dr, A. F. Gazdar, was employed. M-MSV (3 to 5 x 104 focus-forming units [FFU}/0.05 ml) 
was injected intramuscularly (i.m.) in the thigh region into adult mice. 
The M-MuLV was obtained from University Laboratories,  Inc., Highland Park, N.J.,  as a 10% 
cell-free  extract  from  the  spleen of  leukemic  BALB mice  (lot  no.  MLS  15). When titered  on 
sarcoma-positive  leukemia-negative  (S+L -)  cells (11) this preparation contained about 5,6  x  105 
focus-inducing  units (FIU)/ml. The  extract  was  further  diluted  1:10, and 0,05 ml  was  injected 
subcutaneously (s.c.) into AKR mice within 24 h after birth. M-MSV-injected mice were inspected 
twice a week for tumor development and growth. Tumor size was evaluated by measuring the major 
diameter of tumor mass with a caliper and deducting the diameter of the opposite normal thigh. 
Histology.  Some mice were killed when moribund or at selected time intervals.  Representative 
fragments of tumor, spleen, and lymph nodes were removed, fixed in Bouin's or Carnoy's fluid and 
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processed for histological examination. Paraffin sections were stained with hematoxylin-eosin and 
methyl green pyronin. 
Hemolytic Plaque Forming Cell (PFC) Assay.  M-MSV injected and control AKR mice were im- 
munized intraperitoneally (i.p.)  with 4  x  108 sheep red blood cells (SRBC)  (Sclavo-Siena, Siena, 
Italy). The mice were killed on the 5th day after immunization and the number of direct spleen PFCs 
was determined by the method of Jerne et al. (12) with minor modifications. 
Virus  Neutralization.  Virus neutralization was performed by a  focus reduction method (2).  In 
experiments to detect virus neutralizing antibody in the serum of M-MSV-injected mice, blood was 
collected from the retroorbital sinus at intervals after M-MSV injection. Pooled sera, inactivated at 
56°C for 30 min, were incubated at appropriate dilutions with approximately 40 FFU of M-MSV for 
60 min at 22°C and then maintained at 0°C for an additional 30 min. The mixtures were assayed for 
focus formation on DEAE-dextran-pretreated 3T3FL mouse cells, plated the day before at a concen- 
tration of 105 in 60-mm plastic petri dishes. The cultures, in duplicate, were grown in Dulbecco's me- 
dium (Grand Island Biological Company, Grand Island, N.  Y.), supplemented with 10% heat-inac- 
tivated and filtered calf serum and antibiotics. Foci were scored on the 5th day under a microscope. 
A similar procedure was employed to characterize the  MSV pseudotype recovered from AKR and 
C58-induced tumors (for details and typing antisera, see Tables IV,  V, and X). 
Humoral  Cytotoxicity.  Humoral  cytotoxicity was measured by the dye-exclusion method with 
trypan blue {13). Fresh nontoxic rabbit serum at 1:3 dilution was used as the complement source. The 
reaction mixture, consisting of 0.05 ml each of  target cell suspension (5 x  106 cells/ml), antiserum and 
complement, was incubated at 37°C for 45 min with constant shaking. A qualitative absorption was 
carried out as follows:  packed absorbing cells, obtained from primary tumors by teasing the tumor 
mass  and  pressing it  through  a  40-mesh stainless steel sieve,  were  mixed with  an  equal  vol of 
antiserum at 2-3 twofold dilutions below the 50% end point, and incubated for 60 min on ice. The 
residual cytotoxic activity in the supernate was tested as described above using target B6 MBL-2 
(M-MuLV-induced) or  E3G2  (G-MuLV-induced) transplanted leukemia  cells. Antiserum against 
M-MuLV-determined cell surface antigen (MCSA) was obtained from B6 mice immunized i.p. by 
seven weekly injections with increasing doses (5  ×  106 to 5  x  107) of BALB-LSTRA (M-MuLV- 
induced) transplanted leukemia cells. Antiserum against G-MuLV-determined cell surface antigens 
(GCSAs) was obtained by immunizing B6 mice with AKR-K36 spontaneous leukemia, as previously 
reported (14). 
Antilymphocyte  Serum  Treatment.  Rabbit  antimouse lymphocyte serum (ALS)  was obtained 
from Microbiological Associates, Bethesda, Md. (lot no. 13120). AKR mice received 0.20 ml ALS i.p. 
the day before M-MSV injection; 0.10 ml was subsequently given on days 1, 3, 5, 7, 9, 11, and 13 after 
M-MSV injection. 
Results 
Oncogenic Response o[ AKR and C58 Mice to M-MSV.  Since both immune 
reactivity and endogenous MuLV titer might change with age, two age groups of 
AKR and C58 mice were studied. As seen in Table I, the age of mice at M-MSV 
injection did not significantly affect tumor incidence: 46-69% of AKR mice and 
92-94% of C58 mice  developed sarcomas  at the injection site. The mean latent 
period of tumor appearance  was  considerably more prolonged in AKR than in 
C58 mice.  However,  in both strains the majority of sarcomas grew progressively 
and ultimately killed the host. 
The pattern of tumor growth is schematically represented in Fig.  1; again, no 
differences were observed in relation to the age at the time of virus inoculation. 
C58 mice  exhibited a  rapid increase  in size of tumor mass,  and almost all died 
within 4  wk  after  tumor appearance.  Sarcomas  induced  in AKR mice  showed 
variable  behavior.  Considering  the  two  age  groups  together,  18%  of  tumors 
regressed  shortly after  appearance,  55%  grew  slowly but  constantly,  while the CHIECO-BIANCHI ET AL. 
TABLE I 
Development of Sarcomas in AKR and C58 Mice Injected with M-MSV 
1165 
Mice with sarcoma*  Mice with 
Total no.  Mice dead from 
Strain  Age  mice  {mean latent period;  regressed  sarcomas 
days}  sarcomas 
wk  %  %  % 
AKR  6-12  80  69 (41)  20  80 
24-38  24  46 (54)  9  91 
C58  6-12  35  94 (16)  3  97 
24-38  25  92 (17)  0  100 
* Percentage of mice calculated from total number of mice. 
S Percentage of mice calculated from number of mice with sarcoma. 
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Fro. 1.  Different growth behavior of AKR and C58 tumors. A  AKR tumors: 18% regressing, 
55% progressing, 27% persisting; Q, C58 tumors: 98% progressing. 
remaining  27% persisted for long periods, sometimes for several months without 
obvious enlargement.  In the last group of mice death usually occurred from the 
concomitant  leukemia.  It is also noteworthy that  the tumors which eventually 
regressed had a  shorter latency (10-15 days). 
Briefly,  AKR  mice  showed  a  considerable  degree  of  resistance  to  tumor 
induction  following M-MSV inoculation  as indicated by the very long latency. 
However, most of the sarcomas that subsequently arose did not regress. On the 
other hand, C58 mice developed sarcomas with higher incidence, shorter latency, 
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Fro.  2.  C58  tumor.  Note  the  remarkable  pleomorphism  of  the  neoplastic  tissue.  Hema- 
toxylin and eosin.  ×  625. 
FIG.  3.  C58  tumor.  Neoplastic  tissue  mainly composed  of proliferating  cells arranged  in a 
nodular pattern.  Hematoxylin and eosin.  ~  250. 
Histology.  Histological  examination  of AKR  and  C58  tumors  revealed  the 
typical  pleomorphism  and  granulomatous  appearance  of M-MSV-induced  sar- 
comas  (5,  15).  Stellate,  spindle,  giant  straplike  or  racket-shaped  cells  with 
irregular  and  often  multiple  nuclei  were  seen  along  the  muscle  fibers  which CHIECO-BIANCHI ET AL.  1167 
FIG. 4,  AKR tumor. Nodular aggregates of large eosinophilic neoplastic cells surrounded by 
lymphocytes and neutrophils. Hematoxylin and eosin. ×  435. 
Fro. 5.  AKR tumor. Myoblast-like neoplastic cells and scattered residual muscle fibers in a 
tumor field. Hematoxylin and eosin. ×  435. 
appeared  dissociated,  showing  signs  of  atrophy  and  regeneration  (Fig.  2). 
Vascular proliferation as well as cells undergoing degenerative changes and more 
or less marked infiltration by neutrophils, lymphocytes, and macrophages were 
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In some cases, however, in addition to the pleomorphic areas described above, 
the neoplastic tissue showed an unusual nodular pattern. Multiple small nodular 
foci, composed of polygonal tumor cells possessing abundant pale eosinophilic 
cytoplasm with indistinct boundaries and large vesicular nuclei were observed 
and were often surrounded by leukocytes (Figs. 3 and 4). In other fields, diffuse 
proliferation of myoblastic-like cells  was  also  present  (Fig.  5).  Thus  in  these 
M-MSV induced mouse sarcomas, two kinds of tumor growth patterns seemed to 
co-exist: one consists of simultaneous proliferation (probably through continuous 
viral recruitment) of different cell types of mesenchymal origin with a high rate of 
cell  death  and  inflammatory reaction;  the  other  shows  a  nodular or  diffuse 
growth of monomorphic cells,  most likely myoblastic in origin,  reminiscent of 
clonal aggregates. 
It is interesting to note that in all cases examined, even in C58 mice bearing 
rapidly growing progressive  tumors,  the  spleen  was  increased  in  volume and 
presented follicles with large germinal centers and plasmocytoid cells in the red 
pulp.  Similarly,  the  lymph nodes,  mainly homolateral inguinal and  axillary, 
exhibited  in  the  outer  cortex  follicles  with  prominent  germinal  centers  and 
conspicuous plasmocytosis in  the  medullary cords.  The paracortical area  also 
appeared enlarged and contained numerous scattered pyroninophilic cells. 
Immune Reactivity  of AKR and  C58 Mice Injected with M-MSV.  To test 
whether  the  progression  of tumors  was  dependent  on  a  decreased  immune 
reactivity caused by M-MSV, groups of AKR mice were immunized with SRBC 
at 15, 30, or 60 days after M-MSV injection. As shown in Table II, no differences 
were  observed  in  the  number  of  direct  spleen  PFC  between  control  and 
M-MSV-injected  mice.  To  correlate  further  the  immune  reactivity with  the 
oncogenic  response,  the  PFC  assay  was  performed  using  surgically removed 
spleens from a group of 13 mice (not included in Table II), which were immunized 
with SRBC 15 days after M-MSV injection. The follow-up of the individual mice 
did not reveal any variations in the PFC values in regard to sarcoma induction, 
latency and growth, or leukemia development. 
Since the progression of sarcomas could also be due to a specific immunologic 
unresponsiveness, M-MSV injected mice were tested for the presence of virus 
neutralizing antibodies. Groups of eight to ten 6- to 8-wk old AKR and C58 mice 
were bled before and after M-MSV injection. Their sera were pooled and assayed 
in vitro for neutralizing activity against M-MSV. Groups of 6 to 10 BALB and B6 
mice, similarly treated, were used as donors of positive control sera. The results 
are summarized in Table III. 20 days after M-MSV injection, the AKR and C58 
mice produced virus neutralizing antibody titers which were even higher than 
those observed in BALB and B6 mice. It should be noted that by day 40 the 
sarcomas in 8 out of 10 BALB and in 5 out of 6 B6 mice regressed completely. On 
the other hand, the AKR and C58 mice showed the usual tumor response, i.e., 10 
AKR mice were negative on  day 20 and only two of them had small palpable 
masses on day 40; all eight C58 mice had 2-3 mm tumors on day 20, and 8-10 mm 
tumors on day 40. Thus, no immune depression was detected in M-MSV injected 
AKR and  C58  mice  by  comparing  either the  anti-SRBC  response  to  that  of 
uninjected controls, and, more specifically, the virus neutralizing antibody levels 
to those observed in BALB and B6 mice with M-MSV tumors which regressed. 
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TABLE II 
PFC in AKR Mice after M-MSV Injection* 
Days after  No. mice 
M-MSV  tested  PFC/10 e cells~;  PFC/spleen$ 
injection 
15  10  1.841  ±  0.118  3.895  ±  0.113 
30  8  1.796 ±  0.030  3.938 ±  0.062 
60  9  1.787 ±  0.092  3.984 ±  0.131 
--  6  1.727 ±  0.099  3.848 ±  0.130 
* 6-8-wk old mice injected with M-MSV were immunized with SRBC, and 
the number of PFC was determined on the 5th day. 
Log10 ±  standard error of the means of the number of direct PFC. 
TABLE III 
Neutraliz_ation of M-MS V by Sera from 
M-MSV Injected Mice 
Serum donors* 
Neutralization titer$ 
Days afferM-MSV injection 
-1  10  20  40 
1169 
AKR  4  4  64  >__ 64 
C 58  4  4  64  >_ 64 
BALB  >_ 4  16  32  32 
B6  _>4  >_4  16  >_64 
*  6-8-wk old mice were injected with M-MSV, 
Around 40 FFU of M-MSV were mixed with appropriate dilutions of anti- 
serum and the  mixtures after incubation were assayed in 3T3FL cells. 
Neutralization titer is expressed as the reciprocal of serum dilution that 
resulted in a  50% reduction of focus formation. 
The possibility was then considered that the high level of endogenous G-MuLV 
in  AKR  and  C58  tissues  could  influence  the  growth  of  tumors  through  an 
in  vivo  helper  effect.  The  MSV  recovered  from  the  induced  sarcomas  was 
therefore analyzed antigenically by a neutralization assay. 
To determine the specificity of the antisera to be used, a previous neutraliza- 
tion test was carried out on cloned M-MuLV and G-MuLV, using the FIU reduc- 
tion method on S+L  -  cells (11). As shown in Table IV, the reaction was quite spe- 
cific. 
Two AKR and four C58 cell-free tumor extracts were assayed for MSV content 
and  viral  envelope antigenicity  by  a  neutralization  test  on  3T3FL  cells.  All 
tumors examined yielded a considerable amount of MSV (Table V). In all cases, 
the  focus-forming virus was  not affected by the  anti-Moloney serum but was 
completely neutralized by the anti-Gross serum. It was clear that M-MSV itself 
was neutralized and not only the attending MuLV, because in each neutraliza- 
tion  assay  helper  virus  was  added  which  could  not  be  neutralized  by  the 
antiserum used. Thus, a drop in FFU could not be attributed to the elimination 
of the  helper virus necessary for the  detection of two-hit M-MSV foci. These 1170  REDUCTION  OF  MSV  TUMOR REGRESSION  IN  AKR  AND  C58  MICE 
TABLE IV 
Specificity o/Neutralization  by Anti-M-MuL V and 
A n t i- G-MuL V Sera * 
Test virus 
Test antiserum 
Anti-M-MuLV  Anti-G-MuLV 
Vn/Vo  Vn/Vo 
M-MuLV-IC  _<0.01  0.65 
(3T3-cell derived) 
G-MuLV  0.72  0.009 
(3T3-cell derived) 
*The assayed was performed with MuLVs in S+L -  cells as previously de- 
scribed (11).  The nonneutralized fraction, Vn/Vo, was calculated from 
the reduction in FIU. The identical proportion of virus was neutralized 
if the  respective pseudotypes of MSV were assayed as foci in  3T3FL 
cells. Anti-M-$CluLV serum was prepared in Swiss mice inoculated with 
the IC  isolate of M-MuLV which was passed in 3T3  cells (4).  The rat 
anti-G-MuLV serum  was produced as described in (16).  The sera were 
used at 1:50 and 1:250 dilutions, respectively. 
TABLE V 
Neutralization  of Tumor-Derived MS V by Anti-M-MuL V and 
Anti- G-MuL V Sera* 
Test antiserum 
Cell-free tumor 
extract tested  Original titer  Anti-M-  Anti-G-MuLV 
MuLV 
Vn/Vo 
Vn/Vo 
FFU/ml 
AKR  6.1 x  105  0.84  0.005 
AKR  1.0 × 10 ~  1.05  0.005 
C58  7.0 × 105  0.95  0.004 
C58  3.1 × 105  0.91  0.006 
C58  5.1 × l0 s  0.95  0.005 
C58  5.0 × 105  0.81  0.005 
* Between  100-200  FFU  of MSV  were  mixed  with  antiserum and  the 
mixtures were assayed in NIH-3T3  cells to ensure correct tropism for 
potential AKR or C58 MuLV coats. In previous experiments the number 
of loci of M-MuLV (IC)  was essentially identical in NIH-3T3 or 3T3FL 
cells. An optimal MuLV helper inoculation (2  x  104 FIU/0.1 ml) of the 
type opposite to, and not neutralized by the antiserum employed, was 
added to the cells about 1 h after the mixture of MSV and antiserum was 
added. The anti-M-MuLV and anti-G-MuLV sera were used at 1:50 and 
1:250 dilutions, respectively. 
results suggested  that  G-MuLV  pseudotypes  of MSV  were formed  in vivo,  since 
the MSV  recovered  from  AKR  and  C58  tumors  had  the envelope  antigenicity  of 
the endogenous  G-MuLV. 
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recovery of M-MSV coated with G-MuLV from AKR and C58  tumors did not 
necessarily mean that the tumors were in fact induced by this MSV pseudotype. 
To  obtain  direct  evidence  for  the  etiological  role  of  M-MSV  coated  with 
G-MuLV, the specificity of sarcoma cell surface antigens was determined. Cell 
suspensions from two AKR and two C58  sarcomas were incubated with typing 
anti-M- or anti-G-MuLV sera to absorb cytotoxic antibodies. After incubation, 
the  residual  cytotoxic  activity was  tested  at  various  dilutions  on  M-MuLV 
induced MBL°2 or G-MuLV-induced E~G2 leukemia target cells. As controls, the 
MBL-2 and E~G2  reference cells,  as  well as cell suspensions from two BALB 
M-MSV-induced sarcomas were  used  for the qualitative absorption test.  The 
results  are  shown in Table  VI.  AKR and C58  sarcoma cells absorbed out the 
cytotoxic antibody directed against GCSA, but did not affect the activity of the 
TABLE  VI 
Absorption Tests with AKR, C58, and BALB Sarcomas Induced by M-MSV Inoculation: 
Humoral  Cytotoxicity Technique by Trypan Blue Staining against B6 Moloney Leukemia 
MBL-2 and Gross Leukemia E~G2 Cells, used with the Moloney- and Gross-Typing Sera 
Preabsorbed with Various Cells 
Test antiserum 
B6 anti-LSTRA* (M-typing serum)  B6 anti-K365 (G-typing serum)  Cells used  for 
absorption 
Serum dilution  Ab- 
sorp  - 
1/2  1/4  1/8  1/16  tion 
Serum dilution  Ab- 
sorp- 
1/3  1/6  1/12  1/24  tion 
% o/trypan blue  % of trypan blue 
stained cells  stained cells 
None  80  69  53  47  -  62  56  39  28 
MBL-2  <10  <10  <10  <10  +  63  30  21  13 
E3G2  57  39  35  34  -  < 10  < 10  < 10  < 10  + 
AKR-sarcoma  59  41  45  29  < 10  < 10  < 10  < 10  + 
C58-sarcoma  54  47  34  34  -  < 10  < 10  < 10  < 10  + 
BALB-sarcoma  < 10  < 10  < 10  < 10  +  28  23  < 10  < 10  ± 
* LSTRA, transplanted BALB M-MuLV-induced leukemia. 
K36, transplanted AKR spontaneous leukemia. 
anti-MCSA  serum.  On  the  other  hand,  BALB  sarcoma  cells  absorbed  the 
cytotoxicity of the anti-MCSA serum. It is interesting that the latter cells could 
also absorb the activity of the anti-GCSA serum. These findings demonstrated 
that  AKR and  C58  sarcoma cells  possessed surface antigens specified by the 
endogenous G-MuLV. 
Effect of ALS Treatment or M-MuL V Neonatal Infection on Tumor Induction 
by M-MSV in AKR Mice.  From the above studies, it seemed clear that MSV 
with  new  envelope  characteristics  was  etiologically  related  to  the  induced 
sarcomas  in  AKR and  C58  mice.  The  collateral  finding of the  unusual long 
latency of AKR tumorswas, however, unexplained. Among others, the possibility 
that  a  strong  immune  reaction  could  prevent  early tumor  development was 
considered. To investigate this point, experiments were performed with the aim 1172  REDUCTION  OF  MSV  TUMOR  REGRESSION  IN  AKR  AND  C58  MICE 
of depressing the immune response of M-MSV injected mice. 6- to 8-wk old AKR 
mice were given ALS 1 day before and every second day for 2 wk after M-MSV 
injection.  Sarcomas appeared with higher incidence and with a  shorter latent 
period  in  ALS-treated  mice  than  in  controls  (Table  VII).  This  result  would 
indicate that immunodepression by ALS was effective in decreasing the relative 
resistance  of AKR mice to M-MSV.  Alternatively, ALS could have raised the 
titer of endogenous G-MuLV, thus providing more helper for the new pseudotype 
formation. Actually, after such ALS treatment we have found in AKR mice a 
10-fbld  increase  in  the  G-MuLV titer of tail extracts (17) as assayed on S+L  - 
cells. 
Therefore, more substantial evidence was needed to support the immunologic 
basis of the relative resistance of AKR mice to M-MSV. With this purpose, AKR 
mice were given M-MuLV at birth, and subsequently were injected with M-MSV 
when 8 wk old. All mice developed sarcomas in about 2 wk, and seven of them 
died from concomitant leukemia (Table VIII). In the control group, consisting of 
TABLE VII 
Effect of ALS Treatment on Tumor Induction by M-MSV in AKR Mice 
Mice with sarcoma*  Mice with 
Total no.  Mice dead 
Inoculation with:  (mean latent  regressed 
mice  period; days)  sarcomas  from sarcomas 
%  %  % 
M-MSV§  80  69 (41)  20  80 
ALS + M-MSV  29  96.5 (16)  3.5  96.5 
* Percentage of mice calculated from total number of mice. 
S Percentage of mice calculated from number of mice with sarcoma. 
§ Data from Table I. 
mice neonatally injected with M-MuLV, all mice exhibited an earlier onset of 
leukemia and died in less than 4 mo. 
It appeared likely that, in line with previous work (18),  the neonatal injection 
of M-MuLV could have produced a state of partial immunological tolerance (see 
Discussion)  to virus-specified antigens responsible for the accelerated appear- 
ance  of M-MSV  tumors.  This  interpretation was  supported  by the  fact that 
ALS-treated mice could still synthetize considerable amounts of virus neutraliz- 
ing  antibody, whereas  mice  receiving  M-MuLV neonatally and  subsequently 
injected with M-MSV could not (Table IX). 
Finally, the recovery and antigenic typing of MSV from sarcomas arising in 
two ALS-treated and in two M-MuLV neonatally injected mice was attempted. 
As shown in Table X, these early tumors yielded MSV which was neutralized by 
the anti-M-MuLV but not by the anti-G-MuLV serum. Thus, both treatments 
were  able  to  circumvent  the  relative  resistance  of AKR  mice,  allowing  the 
original M-MSV pseudotype to induce tumors with higher incidence and shorter 
latency. CHIECO-BIANCHI ET AL. 
TABLE VIII 
Development o[ Sarcomas in AKR Mice Injected at Birth with M-MuL V 
and as Adults with M-MSV 
1173 
Mice with sar-  Mice dead from 
Mice with  Mice dead 
Total no.  coma* (mean  leukemias§ 
Inoculation with:  regressed  from 
mice  latent period;  (mean latent 
days)  sarcomas  sarcomas  period; days) 
%  %  %  % 
M-MuLV  7  --  --  --  100 (105) 
M-MuLV + M-MSV  10  100 (16)  0  100  70 (87) 
* Percentage of mice calculated from total number of mice. 
Percentage of mice calculated from number of mice with sarcoma. 
§ Percentage of mice dead with leukemia calculated from total number of mice. 
TABLE IX 
Neutralization of M-MSV by Sera from ALS-Treated or M-MuL V NeonataUy Infected 
AKR Mice, Injected with M-MSV 
Neutralization titerS 
Serum donors 
inoculated with:*  Days after M-MSV injection:  - 1  20  30  40 
ALS + M-MSV  ND  16  32  32 
M-MuLV + M-MSV  <8  <8  <8  <8 
M-MSV  <8  32  64  64 
* ALS treatment was started the day before and continued for 2 wk after M-MSV injection. M-MSV 
was injected in 6-8-wk old mice and M-MuLV in newborns. 
S See Table III. 
TABLE X 
Neutralization of AKR Tumor-Derived MSV by Anti-M-MSV and Anti-G-MuL V Sera* 
Tumor extract donors  Original 
inoculated with:  titer 
Test antiserum 
Anti-M-MSV  Anti-G-MuLV 
Vn/Vo  Vn/Vo 
FFU/ml 
ALS +  M-MSV  3.9 x  10'  0.040  0.80 
ALS + M-MSV  1.6 x  104  0.060  0.75 
M-MuLV + M-MSV  1.8 x  105  0.060  0.80 
M-MuLV + M-MSV  2.8 x  10 ~  0.003  0.90 
* The anti  M-MSV serum was obtained from regressor (B6  x  AKR)F1  mice bled 40  days after 
M-MSV injection. The anti G-MuLV was produced in W/Fu rats by eight weekly i.p. injections 
with increasing doses (10 e to 107) of C58(NT)D  transplanted syngeneic leukemia cells. Both sera 
were used at 1:50 dilution since this gave highly specific neutralization reactions in previous experi- 
ments. For additional details of the neutralization assay, See Table V. 1174  REDUCTION  OF  MSV  TUMOR  REGRESSION  IN  AKR  AND  C58  MICE 
Discussion 
While the in vitro relationships between  murine sarcoma and leukemia viruses 
are  well  established,  relatively little  information  is  available  on  their  in  vivo 
interactions. Chirigos et al.  (7, 8)  have reported that co-infection with R-, F-, or 
M-MuLV  increases  the  oncogenicity  of  M-MSV.  Our  previous  results  have 
confirmed and extended these findings (9). Mice neonatally infected with Gi- or 
G-MuLV, and subsequently injected with M-MSV did show higher frequency of 
tumor induction and progressive growth. 
The present studies were performed to determine whether endogenous MuLV, 
when expressed as infectious virus, could influence the oncogenicity by M-MSV. 
It was  found that  after M-MSV  infection in  mice of the high leukemia strains 
AKR  and  C58 which have considerable titers of endogenous G-MuLV early in 
life, the great majority of the induced tumors showed progressive fatal growth. 
Although M-MSV may nonspecifically depress the immune reactivity of the host 
(19),  this  effect  seems  to  play  no  role  in  previous  (9)  as  well  as  in  present 
experiments.  In  fact,  mice  eventually  developing  progressive  tumors  reacted 
normally  to  SRBC  immunization,  and  moreover,  they  could  produce  specific 
M-MSV  neutralizing  antibody  even  better  than  BALB  and  B6  mice  with 
regressed tumors. In preliminary unpublished experiments using a 51Cr.releasing 
cytotoxic  test,  we  have  also  detected  a  considerable  degree  of cell-mediated 
immunity in M-MSV-injected AKR and C58 mice against target leukemia cells 
bearing M-MuLV-specified surface antigens.  These observations, together with 
the  morphological  signs  of marked  reactivity  in  lymph  nodes  and  spleens  of 
tumor-bearing AKR and  C58 mice,  indicate that the failure of tumor regression 
cannot be due to immune depression caused by M-MSV. 
The possibility that AKR mice may be utilized as an in vivo system to rescue the defective 
MSV genome was put forward after the results obtained by Huebner et al.  (20) and by 
Ting and  Law (21)  using,  respectively, hamster or rat  MSV-transformed nonproducer 
cells. However, this was later questioned since the latter cell line (MSB-1) was shown to 
release both focus-forming virus (22)  and a rat-tropic helper type C virus (23). In more 
recent  experiments, ~ Kirsten  (Ki)-MSV  transformed,  nonproducer  K-NRK  rat  cells 
injected i.m. in adult AKR mice induced progressive tumors within 2-3 mo. The tumors 
exhibited the typical morphology of primary MSV-tumors and yielded infectious MSV 
with the usual host range of endogenous N-tropic MuLV. No tumors have been produced 
so far by injecting K-NRK cells in normal adult B6 mice. 
The potential of endogenous G-MuLV to act as helper for the MSV oncogenic activity is 
further substantiated by our present data. These clearly show that the M-MSV injected in 
AKR and C58 mice may undergo a process of phenotypic mixing by acquiring envelope 
antigenicity of the  endogenous helper G-MuLV.  The complete virus neutralization by 
specific anti-G-MuLV serum,  and the capability of the AKR and C58 sarcoma cells to 
absorb the cytotoxicity of the typing antiserum against GCSA makes it highly probable 
that the new MSV pseudotype is actually responsible for the tumor growth. Of interest is 
the behavior of the BALB-M-MSV-induced sarcoma cells in the absorption assay. These 
cells completely removed the cytotoxic activity of the anti-MCSA typing serum and at the 
~Chieco-Bianchi, L., and M. M. Lieber. Unpublished observations. CHIECO-BIANCHI  ET AL.  1175 
same time, also showed absorption of the anti-GCSA serum. As recently found (24), some 
spontaneously  transformed  clones  of  BALB/3T3  and  transplanted  BALB  radiation- 
induced  leukemia  BALB.RL31  release  a  type  C  virus  population  which  shares  type- 
specific viral envelope antigen (VEA) x 1-VEA, and subgroup-specific VEA. Type C virus 
with similar antigenic characteristics is also synthesized by transplanted AKR spontane- 
ous leukemia  K36 which was employed to produce the  G-typing mouse serum.  Conse- 
quently, this virus might be responsible for the induction of GCSA on M-MSV-induced 
BALB sarcoma cells, resulting in the absorption of cytotoxic activity to GCSA. 
The  spontaneous  regression  of  M-MSV-induced  sarcomas  in  mice  as  already  out- 
lined,  is commonly explained in terms of host immune response.  Although in vitro tests 
indicate  that  both  bone  marrow-derived  (B)  and thymus-derived  (T)  lymphocytes are 
cytotoxic,  in  vivo  observations  (25)  suggest  that  the  integrity  of  the  T-lymphocyte 
population is crucial for the M-MSV tumor regression. Besides immunological manipula- 
tion  of the  host,  the  failure  of tumors  to regress  may be  due  to a  number  of factors. 
MSV-transformed  nonproducer  cells  do  not  possess  surface  antigens  detectable  by 
standard serological techniques (26). The same is true for the sarcoma-positive leukemia- 
negative  (S+L -)  line  of  MSV-transformed  cells  that  release  very  low  amounts  of 
noninfectious virus (27). More recently, by using the sensitive procedure of immunoelec- 
tron  microscopy,  one  of  the  authors  (T.  Aoki)  has  been  able  to  demonstrate  an 
MSV-associated cell surface antigen in nonproducer mouse and rat cells transformed by 
Ki- or M-MSV (28). This antigen seems, however, only weakly immunogenic since BALB 
mice preimmunized  with  Ki-MSV-transformed,  nonproducer BALB/3T3 cells were not 
made  resistant  to subsequent  challenge with the  same cells.  On the other hand,  when 
helper  leukemia  virus  was  inoculated  into  the  tumor  mass,  the  transplanted  Ki-MSV 
nonproducer tumors readily regressed (29). It thus appears that only tumor cells actively 
producing type C particles are strongly immunogenic, whereas nonproducer MSV-trans- 
formed  cells  are  unable  to  evoke  an  allograft-like  immune  response.  Since  the  above 
studies have been performed on transplanted  tumor cells, it is difficult to envisage their 
relevance to the behavior of primary tumors. 
In vivo studies  in the avian system with Rous sarcoma virus (RSV)  have shown that 
RSV-producing sarcoma cells have only a limited growth potential and perish after a finite 
number  of divisions  {30).  Accordingly,  it  has  been  suggested  that  progressive  tumor 
growth is largely dependent on release of infectious virus and continuous transformation of 
normal cells. This hypothesis has been supported by results of in vitro experiments on the 
proliferation  dynamics of chicken embryo cells after transformation  by RSV,  Schmidt- 
Ruppin strain (31). RSV-transformed cells after a temporary phase of rapid growth failed 
to survive for any length of time. Added normal cells were rapidly transformed and were 
needed continuously in order to maintain a transformed proliferating cell pool. 
There  is  indirect  evidence  that  also  in  the  mouse,  under  standard  experimental 
conditions,  the growth pattern  of M-MSV-transformed  cells may be essentially similar. 
Histologically, the sarcomatous tissue appears to be derived from a mixture of inflamma- 
tion, cell lysis, and repair involving transformed mesenchymal cells. Although permanent 
cell lines such as 3T3 are easily transformed by M-MSV and may propagate indefinitely in 
vitro  (32),  it  is  difficult to establish  permanent transformed cell lines by infecting with 
M-MSV primary mouse embryo cultures  (33).  Similarly,  it is hard to culture cells from 
M-MSV-induced primary tumors (34). Thus, it may be possible that, as suggested for the 
avian  Rous sarcoma system,  development and growth of M-MSV tumors in the  mouse 
follows  a  nonclonal  kinetics  which  is  dependent  upon  a  constant  high  rate  of virus 
replication  and continuous recruitment of newly infected transformed cells. When virus 
synthesis  is  slowed  down by a  host reaction  or antibody transfer,  prevention  of tumor 
formation  as  well  as  tumor  regression  may  result  (35).  At  variance  with  this  line  of 1176  REDUCTION  OF  MSV  TUMOR  REGRESSION  IN  AKR  AND  C58  MICE 
reasoning is the observation that some of the MSV-induced tumors revealed morphologi- 
cal features  suggesting a  proliferative pattern  of the  clonal type.  Since only a  limited 
number of tumors has been examined histologically, more studies are needed to determine 
if this  represents  a  rare  event or,  more  interestingly, another  peculiar property of the 
progressive  sarcomas  arising  in  AKR  and  C58  mice.  At  present,  however,  a  likely 
explanation  for  the  lack  of  regression  in  AKR  and  C58  mice  is  that  immunologic 
unresponsiveness, either apparent or actual, which is specific for the antigens coded by the 
endogenous G-MuLV, makes for a  poor host immune response against the newly formed 
M-MSV coated with G-MuLV pseudotype. Both viral antigen released in the body fluids 
and antibodies bound to G-MuLV as immune complexes are known to occur in AKR mice 
(36)  and  may be responsible for mimicking a  state of immunological tolerance.  On the 
other  hand,  evidence  of  a  real  specific  unresponsiveness  selectively  affecting  the  T 
lymphocytes  present  in  mice  neonatally  infected  with  M-MuLV  has  been  recently 
obtained (18). That the latter mechanism also holds for AKR and C58 mice remains to be 
elucidated. 
As an alternative explanation for the failure of tumors to regress, the possibility should 
be considered that  by growing in  AKR or C58  host  cells, MSV  may also acquire  from 
G-MuLV in addition to the viral envelope new genetic information which may modify its 
biologic and pathogenic properties. Differences in the immunogenicity and oncogenicity of 
different stocks of M-MSV  (37)  and  Ki-MSV  (29),  as reflected in the pattern of tumor 
growth,  are known. No indications are available, however, as to whether they depend on 
variation in the intrinsic characteristics of the virus or on different ratios between MSV 
and  helper populations. In this regard, it is noteworthy that the Harvey isolate of MSV 
induces sarcomas which rarely regress and these tumor cells may be easily kept in cultures 
for long periods (5). 
The fact that AKR mice had sarcomas after a long latent period has been interpreted to 
be a result of relative resistance to M-MSV infection. At first sight this might be due to an 
interference phenomenon  between  the endogenous  G-MuLV growing in  AKR cells and 
M-MSV. In vitro preinfection of mouse embryo fibroblasts with G-MuLV induced resist- 
ance to infection and transformation not only with the respective M-MSV coated with G- 
MuLV but also with M-MSV (M-MuLV)  pseudotype (38). However, to our knowledge no 
clear demonstration for interference has been described as occurring in vivo, and more im- 
portantly,  C58  mice, which show a  similar high expression of endogenous G-MuLV, did 
not exhibit such a  delayed sarcoma appearance. Therefore,  it is likely that factors other 
than viral interference are responsible for the observed resistance. That a number of cellu- 
lar genes control the expression of endogenous MuLVs as well as the host's susceptibility 
to infection and neoplastic transformation is firmly established (39). Specifically, the Fv-1 
gene  controls  the  relative resistance of MuLVs.  NIH  Swiss (N)  cells carrying the Fv-1  n 
allele propagate  "N-tropic"  viruses  more  efficiently, whereas  BALB  (B)  cells, with the 
Fv-1  b allele, are more susceptible to "B-tropic" viruses. M-MuLV, on the other hand,  is 
NB tropic as are other passaged strains of MuLVs,  and it can grow equally well in both 
cell types.  Accordingly, no  restriction on  M-MSV  infection should be exerted by AKR 
cells carrying the Fv-1  n genotype. 
The  influence of the  immune  response  (It)  genes  on  the  capability of mice to react 
immunologically to a  variety of natural and synthetic antigens is also well documented. 
For instance, the It-1 gene, which has been mapped near the K  end of the H-2 region, is 
closely associated with or identical to the Rgv-1 gene which, in turn, seems to determine 
the  strength  of the  immune  response  to  MuLV-specified antigens  (39,  40).  Thus,  it is 
conceivable that  AKR resistance to M-MSV  is sustained by immunologic phenomena. 
The  results  of  ALS  administration  or  M-MuLV  neonatal  infection  on  latency  and 
incidence  of M-MSV-induced  tumors  would  support  this  hypothesis.  Both  treatments CHIECO-BIANCHI ET AL.  1177 
shortened  the  latent  period  and  increased  the  tumor  yield,  probably  by  rendering 
primarily the  T-lymphocyte population  unresponsive  through  nonspecific  or  specific 
mechanisms (18, 41). Moreover, the MSV recovered from these early tumors proved to be 
the original Moloney pseudotype. 
In conclusion, the data reported indicate that AKR and C58 type C endogenous 
viruses can compete successfully with exogenous M-MuLV as helpers for in vivo 
MSV  replication. The  resulting MSV  sarcomas  interestingly enough lack the 
unique property of spontaneous regressions and behave very much like conven- 
tional tumors. Whether the helper effect is exerted by viruses with the usual N- or 
B-tropism,  or  by  the  newly  isolated  xenotropic,  "S-tropic"  viruses  (42,  43) 
presents an interesting point for further investigation. 
Summary 
Adult AKR  and C58 mice injected intramuscularly  with murine  sarcoma  virus, 
Moloney  isolate  (M-MSV),  developed  high  incidence  of nonregressing  local 
tumors.  Histologically,  these  tumors  revealed  the  typical  pleomorphism  of 
M-MSV  sarcomas;  in some cases, however, neoplastic tissue showed a nodular or 
diffuse growth  of monomorphic  myoblastlike  cells, reminiscent  of clonal aggre- 
gates. No depression of immune  reactivity was found in M-MSV-injected  mice as 
evaluated  by  direct  hemolytic  plaque-forming  cells against  SRBC  and  by 
virus-neutralizing  antibody  production. 
The MSV  recovered from the induced  tumors proved to be, by neutralization 
assay, a Gross (G)-MSV  pseudotype.  Moreover,  tumor cell  suspensions absorbed 
out cytotoxic antibody  directed against G-cell surface antigens. Therefore,  the 
conclusion was drawn that MSV  with envelope  characteristics of endogenous  G 
leukemia  virus had formed  in vivo through  a phenotypic  mixing  phenomenon. 
The failure of tumors to regress has been interpreted as mainly due to the partial 
unresponsiveness  of  host immune  reactivity towards G-MuLV  specified antigens. 
Since MSV-tumors  arose in AKR  mice  after a very long latent period, the 
possibility  was  considered  that  this  relative  resistance  might  depend  on 
immunologic  mechanisms.  In  fact, M-MSV-injected  AKR  mice  immunode- 
pressed by goat antimouse  lymphocyte  serum  or rendered  partially tolerant by 
neonatal  M-MuLV  inoculation  developed  sarcomas  with higher incidence  and 
with a shorter latency. Furthermore,  the MSV  recovered from these early tumors 
proved to be the original Moloney  pseudotype. 
Received for publication 2 July 1974. 
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